C-reactive protein and interleukin-6 are elevated in onchocerciasis patients after ivermectin treatment.
Ivermectin treatment of onchocerciasis can induce adverse reactions. Mechanisms underlying these reactions are poorly understood but may include activation of neutrophils. This study investigated the acute-phase response in onchocerciasis patients during 2 days after ivermectin treatment. The acute-phase protein C-reactive protein (CRP) and cytokines that mediate the acute-phase response (tumor necrosis factor-alpha [TNF alpha] and interleukin-6 [IL-6]) were measured in 144 skin snip-positive onchocerciasis patients and 12 skin snip-negative controls who received one dose of ivermectin (150 micrograms/kg). No elevated TNF alpha levels were found, but IL-6 and CRP were elevated in 25.7% and 50.7% of the patients, respectively, after ivermectin treatment. Most patients (89.2%) with raised IL-6 also had raised CRP. Such increases were not observed in controls and in patients were correlated with adverse reactions and microfilarial densities. These findings suggest a possible role of the acute-phase response in microfilarial destruction following ivermectin treatment.
Njoo
F L
FL
Department of Ophthalmo-Immunology, Netherlands Ophthalmic Research Institute, Amsterdam.
Hack
C E
CE
Oosting
J
J
Luyendijk
L
L
Stilma
J S
JS
Kijlstra
A
A
D015415:Biomarkers / Q000097:blood; D002097:C-Reactive Protein / Q000032:analysis* / Q000378:metabolism; D004797:Enzyme-Linked Immunosorbent Assay; D006801:Humans; D005779:Immunodiffusion; D015850:Interleukin-6 / Q000097:blood*; D007559:Ivermectin / Q000009:adverse effects / Q000627:therapeutic use*; D009855:Onchocerciasis / Q000097:blood* / Q000188:drug therapy* / Q000503:physiopathology; D012016:Reference Values; D013997:Time Factors; D014409:Tumor Necrosis Factor-alpha / Q000032:analysis / Q000378:metabolism
D015415:Biomarkers; D015850:Interleukin-6; D014409:Tumor Necrosis Factor-alpha; D007559:Ivermectin; D002097:C-Reactive Protein